prostatectomy were not associated with the SAS. Conclusions: Lower SAS values indicate patients at risk for adverse events after ORRP. The SAS might serve as one variable for outcome assessment, reflecting the challenge of mutual surgical and anesthesiology procedure management.
Introduction
Radical prostatectomy is a standard treatment for localized prostate cancer (PCA). Applying a standardized reporting methodology, like the modified Clavien-Dindo classification (CDC) [1] , it is found that the overall complication rate of the procedure can be as high as 42.5% [2] . Easily applicable objective models that evaluate the postoperative risk of morbidity and mortality of radical prostatectomy are rare. Established risk factors for complications are age, body-mass-index, and a pelvic lymphadenectomy [3, 4] . Recently the Surgical Apgar Score (SAS) [5, 6] , calculated of predetermined point values assigned to intraoperative estimated blood loss, lowest heart rate (LHR) and lowest mean arterial pressure (MAP; table 1 ) was published. The SAS ranges from 0 to 10 with lower SAS scores indicating an adverse postop-erative outcome [5, 6] . Only a few publications investigated the applicability of the SAS to predict morbidity and mortality of urologic surgical procedures. Ito et al. [7] demonstrated that patients who underwent renal mass excision were 3.7 times more likely to experience a major complication when the SAS was lower than 4, and 24 times more likely to die within 90 days of surgery as compared to those with a SAS ≥ 8. In patients who underwent radical cystectomy Prasad et al. [8] showed a progressive decrease in complications with increasing SAS. We sought to evaluate the practicability of the SAS to predict perioperative adverse events (PAE) of robot-assisted laparoscopic transperitoneal radical prostatectomy (RARP) and open retropubic radical prostatectomy (ORRP) within 30 days of surgery.
Patients and Methods
After receiving the approval of the Ruhr-University Bochum Ethics Committee , PAE in all patients scheduled for radical prostatectomy between September 2010 and March 2013 at a single-university center were retrospectively collected from patient files including the surgeons note, anesthesia protocol and outpatient records. All intraoperative adverse events were graded according to the Satava approach [9] and pre-and postoperative adverse events were classified according to the CDC [1] . Pre-, intra-and postoperative adverse events were combined to PAE and grouped in any (CDC1-5), low-(CDC1-2) and high-grade (CDC3-5) events, respectively. All available PAE within 30 days of postoperation were included. In patients with multiple PAE, only the highest grade was used for statistical analyses. The SAS was calculated as described previously [5, 6] ( table 1 ) from the anesthesia records and the surgical report. The variables for SAS were collected after anesthesia induction from incision to wound closure. Patients with lower scores are considered to be at a higher risk for adverse outcomes [5, 6] . The surgical approach used (RARP or ORRP) was subjectively decided by patients and surgeons. RARP was performed as described by Menon et al. [10] with minor modifications made by a single surgeon and ORRP was performed as described by Budäus et al. [11] , with minor modifications made by 4 different surgeons of whom 3 had the experience of having performed more than 500 previous procedures. In the absence of contraindications, anesthesia administered for RARP and ORRP was performed using a combined anesthesia technique. A lumbar epidural catheter for intraand postoperative analgesia was placed and an effective dose of 10 ml Bupivacaine 0.5% administered, which was repeated every 2 h. General anesthesia was induced with fentanyl, propofol and rocuronium. The patient was then intubated. Anesthesia was maintained by applying desflurane. No specific intraoperative fluid management regime was preferred during the study period. Uni-and multivariable binominal logistic regression analyses were used to identify the association between assumed and previously described risk factors for PAE. The analyses were performed for patients who underwent ORRP and RARP, separately. The SAS was included in the models as continuous variable, assuming a linear relationship between the score and the odds of a PAE. As the SAS is driven by blood loss, a sensitivity analysis was performed excluding cases with perioperative blood transfusion. Additionally, specific complications as shown in table 2 were evaluated. All statistical analyses were performed using SPSS 23 (IBM Corporation, Armonk, N.Y., USA). A p < 0.05 was considered statistically significant.
Results
During the study period, n = 1,006 radical prostatectomies were performed. A complete set of anesthesia records was available for 98.8% (994/1,006). These patients resembled the study population. Clinical and histopathological parameters of the patient collective are shown in table 3 .
Results of the ORRP Population
A total of 609 PAE was observed in 775 patients. Of those, 99.7% (607/609) occurred postoperatively. Of 9 intraoperative PAE, 44.4% (4/9) were Satava grade I and 55.6% (5/9) Satava grade II. Satava grade II events were ureteral lesions (n = 2), rectal laceration (n = 1), bladder * The SAS was calculated from the time of incision to the time of wound closure, from the estimated blood loss, lowest mean arterial pressure, and lowest heart rate entered in the anesthesia protocol during the operation. The score is the sum of the points from each category.
† Occurrence of pathologic bradyarrhythmia, including sinus arrest, atrioventricular block or dissection, junctional or ventricular escape rhythms, and asystole also received 0 points for the lowest heart rate. Values are me dian (IQR) or n (%). ADT = Androgen deprivation therapy; BMI = body mass index; cT = clinical T-stage; EBL = estimated blood loss; MAB = lowest intraoperative mean arterial blood pressure; pN = pathologic N-Stage; PSA = prostate-specific antigen; pT = pathologic T-stage. (19/775) had a SAS ≤ 4. The mean SAS was significantly higher in patients with no adverse events (6.93 ± 1.04) and lower in patients with any and CDC1-2 PAE (6.62 ± 1.17 and 6.62 ± 1.18; p < 0.001, respectively. Figure 1 a shows the distribution of percentages of any, CDC1-2 and CDC3-5 PAE over given SAS values.
In the univariable analyses, lower SAS scores were associated with any and CDC1-2 PAE with p < 0.001 respectively (data not shown). In the ORRP cohort, a lower SAS was associated with bleeding complications (p < 0.001; 67 cohort, the SAS was not associated with any, CDC1-2, and CDC3-5 PAE (data not shown). Multivariable analysis was performed controlling for variables that were found to be significant on univariable analysis; results are shown in table 5 . In the ORRP cohort, the SAS was associated with any and CDC1-2 PAE (OR 0.76, 95% CI 0.66-0.88; p < 0.001 and OR 0.79, 95% CI 0.69-0.91; p = 0.001, respectively). In the RARP cohort, lower SAS scores were not associated with any, CDC1-2 and CDC3-5 PAE with p > 0.05 (data not shown). Also, the SAS was not associated with specific complications (p > 0.05, respectively; table 2 ). In the sensitivity analyses of the RARP cohort, the SAS was not associated with any, CDC1-2, and CDC3-5 PAE (data not shown).
Results of the RARP Population

Discussion
By applying the SAS score and using a standardized assessment of intra-and postoperative adverse events in a contemporary series of patients undergoing radical prostatectomy for localized PCA, we found lower SAS scores in patients with any PAE. The SAS was an independent predictor of any and CDC1-2 PAE, whereas CDC3-5 PAE did not have any predictors. However, this was true only for ORRP patients; PAE in RARP patients were not associated with the SAS. To the best of our knowledge, no other report exists, which applies the SAS in a radical prostatectomy setting. Our results are supported by Prasad et al. [8] who found a progressive de- crease in complications in patients with increasing SAS in a series of 155 consecutive patients who underwent radical cystectomy. In this series, the SAS was also associated with major complications, as defined by the National Surgery Quality Improvement Program [12] , which occurred in 26% of the study population. However, due to the complexity of radical cystectomy, these patients are prone to major or CDC3-5 complications [13] . Prasad et al. [8] did not perform multivariable analyses due to a limited number of cases in that series. In a recently published series of 886 patients with renal mass excision, Ito et al. [7] found that patients with an SAS ≤ 4 were 3.7 times (95% CI 1.42-9.54, p = 0.01) more likely to experience a major complication when compared to patients with an SAS ≥ 8. In our series, a lower SAS was not independently associated with CDC3-5 PAE. Patients who are scheduled for radical prostatectomy are generally in a better health condition compared to patients who undergo radical cystectomy or renal mass excision. Our finding might be supported by an analysis [14] of 123,864 surgical procedures that showed that patients who underwent a urologic procedure had a weaker association of SAS and the probability to die within 7 days after surgery. The mortality rate of the latter study and our study (0.5 and 0.1% at 30 days, respectively) are comparable. However, no information on the performed type of urologic procedures was available in this report. Other nonurologic surgical disciplines that applied the SAS also found that patients with lower scores had a higher incidence of complications. Urrutia et al. [15] applied the SAS to a group of 280 patients undergoing spine surgery. They found a major complication rate as defined by Gawande et al. [5] of 17.4% (4/23) in patients with an SAS ≤ 4, which resembled a 10.61 increased relative risk (95% CI 1.25-90) of suffering a complication compared to patients with an SAS of 9-10. In the validation study of the SAS in 4,119 patients with general or vascular surgery, Regenbogen et al. [6] found major complications in 56.3% (72/128) of the patients with an SAS ≤ 4 compared to 5.0% (72/1,441) with a score ≥ 9 (relative risk 11.3, 95% CI 8.6-14.8; p < 0.001). A comparison of the aforementioned reports to our series is difficult due to the different surgical procedures and patient collectives. Additionally, these were focused only on major complications or death and did not address the incidence of any PAE and their correlation with the SAS. Also, there was no standardized reporting system for complications applied. Almost all of the mentioned studies used an SAS ≤ 4 as cut-off value to define patients at utmost risk for major adverse events and or death. Because there were only 20 patients with an SAS ≤ 4 in our patient collective, we decided against a categorization and applied a continuous SAS in our statistical models. In our series, 2 different surgical approaches are analyzed. Based on baseline population differences and multiple surgeons at different learning stages, a direct comparison of these 2 approaches is not possible. The finding of differences in complication rates between the 2 procedures is backed by literature [2, 16, 17] . Underlying reasons might be a higher incidence of asymptomatic lymphoceles and prolonged catheterization rates, which occurred more frequently with ORRP. Additionally, surgical site infections requiring a revision occurred almost solely with ORRP. Interestingly, a worse American Society of Anesthesiologists (ASA) did predict highgrade PAE, whereas increasing age did not. However, increasing age was associated with any and low-grade PAE. The underlying reasons for this observation are not completely clear. Increasing age is associated with a higher ASA score in our population (data not shown). However, as age was included as a continuous variable in the models, the relatively low frequency of high-grade PAE compared to any/low-grade PAE might result in a non-significant result. Baseline patient characteristics indicate a clear selection bias for patients undergoing RARP with more favorable clinical and histopathological parameters ( table 3 ) . RARP patients were younger than ORRP patients and this may have led to a lower complication rate. Further, younger patients might have more capacity to deal with the stress of surgery [18] . Vice versa, the SAS might be influenced even by the surgical approach. In patients with pneumoperitoneum and steep Trendelenburg position, the MAP may be increased by up to 25% [19] . In our study, patients with RARP had an intraoperatively increased MAP (66 mm Hg). However, we are unable to assess the extent to which the latter finding restricts the applicability of the SAS to RARP patients.
Our study is not devoid of limitations. A first important aspect is the substantial influence of the anesthetists' management with respect to blood pressure and heart rate control. On the one hand, general and epidural/local anesthetic drug effects are accompanied with circulatory depression as insufficient depth of anesthesia may result in stress response-related hypertension. Because the induction period of anesthesia is frequently associated with these hemodynamic response changes affecting the SAS, we only assessed MAP and LHR values during the time period starting from incision until the time of wound closure. Second, there is increasing evidence, that intraoperative fluid management may have an impact on adverse events and mortality rates after surgery [20] . As our patients were not receiving a restrictive or goal-directed fluid management that might be beneficial and associated with fewer PAE, this might introduce an additional bias to our results. However, in the original SAS study [5] and also in the validation study [6] , intraoperative fluid volume has not been addressed. A third important aspect is the patient's preoperative hemodynamic status. In vascular or trauma surgery, intraoperative tachycardia and hypotension are encountered more frequently and are associated with a poorer outcome. This may explain the better fit of the SAS as a predictor for mortality and high-grade PAE in these patient collectives [6, 14] . Our patients were screened preoperatively through electrocardiogram, exercise electrocardiogram and the pulmonary function test to identify obvious cardio-pulmonal morbidity, which is considered a contraindication for radical prostatectomy, and the exclusion of patients with serious cardiac comorbidity might result in presumably more stable hemodynamic conditions indicated by higher SAS scores intraoperatively. A significant proportion of adverse events of radical prostatectomy occurs well after 30 days [16] . As our follow-up was limited to 30 days, especially CDC3-5 PAE requiring surgical interventions, such as bladder neck stricture or urethral stricture, are not included because these often occur well after 30 days. However, the SAS was designed primarily to predict early adverse events. Additionally, we are unable to assess the impact of the length of hospital stay on the occurrence of complications. A prolonged stay has been associated with an increased occurrence of PAE. Vice versa PAE may prolong the hospital stay as well. We are unable to determine to which extent this limitation influences our results. Finally, readmissions to other hospitals or other physician consultations were not assessed, resulting in a possible underreporting of adverse events. The strength of our study lies in the thorough and very detailed standardized assessment of complications in a large contemporary series of open retropubic and RARP.
Conclusion
Lower SAS values identify patients at risk for any PAE after open radical prostatectomy. It might serve as an objective variable of the intraoperative course and create individualized handover processes to assess the need for an intensified postoperative care. However, the SAS is reflecting the challenge of mutual surgical and anesthesiology procedure management in the perioperative setting. A specific cut-off value for prostatectomy patients has to be determined and the influence of other parameters such as the surgical approach and intraoperative fluid management on postoperative adverse events warrants further evaluation, ideally in a multicentric setting.
